Palomar Medical to Market Quantel's SINON Tattoo Removal Laser in the United States and Canada
11 5월 2009 - 11:00PM
PR Newswire (US)
BURLINGTON, Mass., May 11 /PRNewswire-FirstCall/ -- Palomar Medical
Technologies, Inc. (NASDAQ:PMTI), a leading researcher and
developer of light-based systems for cosmetic treatments, announced
today that it has entered into a Distribution Agreement with
Quantel SA (Euronext: QUA), a leading manufacturer of solid state
lasers, for Quantel's SINON(TM) Q-switched ruby laser system for
tattoo removal in the United States and Canada. The SINON
Q-switched ruby laser was developed by Quantel Derma GmbH (formerly
WaveLight Aesthetic GmbH) based in Erlangen, Germany. Its speed and
clinical efficacy make the SINON the choice of leading experts in
aesthetic dermatology for tattoo removal. The SINON(TM) Q-switched
ruby laser will be exclusively marketed by Palomar in the United
States and Canada. Quantel Derma USA based in Bozeman, Montana will
be in charge of installation and technical support of the systems.
Chief Executive Officer Joseph P. Caruso commented, "We are pleased
to become the exclusive distributor for Quantel Derma's SINON
Q-Switched ruby laser for tattoo removal in the United States and
Canada. With the shortest pulse and highest peak power of all ruby
lasers available, the SINON ruby laser is optimized to treat the
more complex and difficult to remove tattoos you see today." Alain
de Salaberry, Quantel's President Director General said, "Its
strong sales force and its experience with Q-switch ruby lasers
make Palomar an ideal partner for the marketing of Quantel's SINON
system." About Palomar Medical Technologies, Inc.: Palomar is a
leading researcher and developer of light-based systems for
cosmetic treatments. Palomar pioneered the optical hair removal
field, when, in 1997, it introduced the first high-powered laser
hair removal system. Since then, many of the major advances in
light-based hair removal have been based on Palomar technology. In
December 2006, Palomar became the first company to receive a 510(k)
over-the-counter (OTC) clearance from the United States Food and
Drug Administration (FDA) for a new, patented, home use,
light-based hair removal device. OTC clearance allows the product
to be marketed and sold directly to consumers without a
prescription. There are now millions of light-based cosmetic
procedures performed around the world every year in physician
offices, clinics, spas and salons. Palomar is testing many new and
exciting applications to further advance the hair removal market
and other cosmetic applications. Palomar is focused on developing
proprietary light-based technology for introduction to the mass
markets. Palomar has granted The Procter & Gamble Company a
non-exclusive License Agreement to certain patents, technology and
FDA documents related to the home-use, light-based hair removal
field for women. In addition, Palomar has an exclusive development
and license agreement with Johnson & Johnson Consumer Companies
to develop and potentially commercialize home-use, light-based
devices for reducing or reshaping body fat including cellulite,
reducing the appearance of skin aging, and reducing or preventing
acne. About The Quantel Group: Founded in 1970, the QUANTEL Group
has over the last 10 years established itself as one of the world's
leading specialists for scientific (research laboratories,
universities), industrial (micromachining, metrics, military) and
medical (ophthalmology, dermatology) laser technologies. This press
release contains forward-looking statements within the meaning of
the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements are based on the Company's current
expectations, plans, intentions, beliefs or predictions. These
forward-looking statements are neither promises nor guarantees, but
involve risk and uncertainties that may individually or mutually
impact the matters herein, and cause actual results, events and
performance to differ materially from such forward-looking
statements. These risk factors include, but are not limited to,
results of future operations, technological difficulties in
developing or introducing new products, the results of future
research, lack of product demand and market acceptance for current
and future products, the effect of economic conditions, challenges
in managing joint ventures and research with third parties and
government contracts, the impact of competitive products and
pricing, governmental regulations with respect to medical devices,
including whether FDA clearance will be obtained for future
products and additional applications, the results of litigation,
including patent infringement lawsuits, difficulties in collecting
royalties, potential infringement of third-party intellectual
property rights, factors affecting the Company's future income and
resulting ability to utilize its NOLs, and/or other factors, which
are detailed from time to time in the Company's SEC reports,
including the report on Form 10-K for the year ended December 31,
2008 and the Company's quarterly reports on Form 10-Q. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. The Company
undertakes no obligation to release publicly the result of any
revisions to these forward-looking statements that may be made to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events. Contacts: Kayla Castle
Sanford Lane Investor Relations Manager Chief Executive Officer
Palomar Medical Technologies, Inc. Quantel Derma USA, Inc.
781-993-2411 508-654-0310 DATASOURCE: Palomar Medical Technologies,
Inc. CONTACT: Kayla Castle, Investor Relations Manager of Palomar
Medical Technologies, Inc., +1-781-993-2411, ; Sanford Lane, Chief
Executive Officer of Quantel Derma USA, Inc., +1-508-654-0310,
Copyright
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024